Curt Mikael von Euler-Chelpin
Director/Board Member presso DICOT AB
Profilo
Curt Mikael von Euler-Chelpin is currently the Chief Executive Officer at KDev Oncology AB.
He is also the Chief Executive Officer & Director at M Von Euler Consulting AB, an Independent Director at Dicot AB, a Director at Annexin Pharmaceuticals AB, a Director at Bostadsrättsföreningen Mälarvik, a Faculty Member at The Royal College of Physicians, and the Chief Medical Officer & VP-Clinical Development at Akinion Pharmaceuticals AB.
Previously, Dr. von Euler-Chelpin served as the Chief Executive Officer at Axelar AB.
He was also the Director of Clinical Strategy at AstraZeneca PLC and AstraZeneca AB.
Additionally, he worked as a Principal at Hoffmann-La Roche, Inc. and Vice President-Oncology MDC at GlaxoSmithKline, Inc. He held the position of Senior Vice President at Aprea Therapeutics AB and Vice President-Oncology at GlaxoSmithKline AB.
He was the Head-Cluster at Roche AB and the Chief Medical Officer & Head-Research at Targovax Oy.
Dr. von Euler-Chelpin obtained a doctorate degree from Karolinska Institutet.
Posizioni attive di Curt Mikael von Euler-Chelpin
| Società | Posizione | Inizio |
|---|---|---|
| DICOT AB | Director/Board Member | 16/04/2018 |
| ANNEXIN PHARMACEUTICALS AB | Director/Board Member | - |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Chief Executive Officer | - |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Chief Tech/Sci/R&D Officer | - |
| The Royal College of Physicians | Corporate Officer/Principal | - |
M Von Euler Consulting AB
 M Von Euler Consulting AB Miscellaneous Commercial ServicesCommercial Services M Von Euler Consulting AB operates as a scientific and technical research & development organization. M Von Euler Consulting AB is based in Stockholm, Sweden. Curt Mikael von Euler-Chelpin has been the CEO of the Swedish company since 2014. | Chief Executive Officer | 15/12/2014 |
Bostadsrättsföreningen Mälarvik
 Bostadsrättsföreningen Mälarvik Miscellaneous Commercial ServicesCommercial Services Bostadsrättsföreningen Mälarvik operates as a housing association. | Director/Board Member | 18/12/2015 |
Precedenti posizioni note di Curt Mikael von Euler-Chelpin
| Società | Posizione | Fine |
|---|---|---|
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | 01/09/2017 |
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Chief Tech/Sci/R&D Officer | 01/09/2012 |
| ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Curt Mikael von Euler-Chelpin
| Karolinska Institutet | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| DICOT AB | Health Technology |
| ANNEXIN PHARMACEUTICALS AB | Health Technology |
| Aziende private | 12 |
|---|---|
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Health Technology |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Axelar AB
 Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
GlaxoSmithkline AB
 GlaxoSmithkline AB Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AB is a Swedish pharmaceutical company that manufactures pharmaceutical products. | Health Technology |
Roche AB
 Roche AB Pharmaceuticals: MajorHealth Technology Part of Roche Holding AG, Roche AB is a biotechnology company founded in 1896. The private company is based in Solna, Sweden and creates innovative treatments to help millions of patients worldwide. Roche actively seeks partnerships with healthcare providers, academia, patient associations, organizations, external companies, and startups to identify needs that form the basis for collaborations. Roche is one of the world's largest research-based biotechnology companies, focusing on advancing science to improve people's lives. The Swedish company develops both drugs and diagnostics and has great respect for the multiple perspectives required to create tomorrow's healthcare. | Health Technology |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Health Technology |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Commercial Services |
M Von Euler Consulting AB
M Von Euler Consulting AB Miscellaneous Commercial ServicesCommercial Services M Von Euler Consulting AB operates as a scientific and technical research & development organization. M Von Euler Consulting AB is based in Stockholm, Sweden. Curt Mikael von Euler-Chelpin has been the CEO of the Swedish company since 2014. | Commercial Services |
Bostadsrättsföreningen Mälarvik
Bostadsrättsföreningen Mälarvik Miscellaneous Commercial ServicesCommercial Services Bostadsrättsföreningen Mälarvik operates as a housing association. | Commercial Services |
- Borsa valori
- Insiders
- Curt Mikael von Euler-Chelpin
